These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 14740779)

  • 21. Drug-eluting stents and glycoprotein IIb/IIIa inhibitors: combination therapy for the future.
    Leon MB; Bakhai A;
    Am Heart J; 2003 Oct; 146(4 Suppl):S13-7. PubMed ID: 14564301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug-eluting stents for in-stent restenosis and acute myocardial infarction: present data from nonrandomized studies.
    Schofer J; Bode C; Silber S
    Herz; 2004 Mar; 29(2):195-200. PubMed ID: 15057441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts?
    Buellesfeld L; Grube E
    Herz; 2004 Mar; 29(2):167-70. PubMed ID: 15054589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of a sirolimus-eluting stent to treat failure of a nonpolymer release paclitaxel-eluting stent implanted for in-stent restenosis.
    Porto I; Banning AP
    J Invasive Cardiol; 2005 May; 17(5):270-3. PubMed ID: 15879608
    [No Abstract]   [Full Text] [Related]  

  • 25. Drug-eluting stents: the panacea for restenosis?
    Lim MC
    Singapore Med J; 2004 Jul; 45(7):300-2. PubMed ID: 15221043
    [No Abstract]   [Full Text] [Related]  

  • 26. [Safety and current indications during "real life" use of sirolimus-eluting coronary stents in Germany. Results from the prospective multicenter German Cypher Registry].
    Zahn R; Hamm CW; Zeymer U; Schneider S; Nienaber CA; Richardt G; Kelm M; Levenson B; Bonzel T; Tebbe U; Schöbel WA; Sabin G; Senges J;
    Herz; 2004 Mar; 29(2):181-6. PubMed ID: 15057439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent.
    Beijk MA; Piek JJ
    Expert Rev Med Devices; 2007 Jan; 4(1):11-21. PubMed ID: 17187467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sirolimus-eluting stent implantation in a heart transplant recipient.
    Tomai F; Gagliardi G; Proietti I
    Ital Heart J; 2004 May; 5(5):408-9. PubMed ID: 15185909
    [No Abstract]   [Full Text] [Related]  

  • 29. [Drug-eluting stents and other anti-restenosis devices].
    Moreno R
    Rev Esp Cardiol; 2005 Jul; 58(7):842-62. PubMed ID: 16022816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-eluting stent for the treatment of small coronary lesion: comparison between sirolimus- and paclitaxel-eluting stent.
    Li JJ; Xu B; Yang YJ; Chen JL; Qiao SB; Ma WH; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Gao RL
    Chin Med J (Engl); 2007 Apr; 120(7):569-73. PubMed ID: 17442204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative clinical outcomes of paclitaxel- and sirolimus-eluting stents: results from a large prospective multicenter registry--STENT Group.
    Simonton CA; Brodie B; Cheek B; Krainin F; Metzger C; Hermiller J; Juk S; Duffy P; Humphrey A; Nussbaum M; Laurent S;
    J Am Coll Cardiol; 2007 Sep; 50(13):1214-22. PubMed ID: 17888837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Percutaneous stenting of the left main with drug eluting stents for in-stent restenosis: immediate- and long-term results.
    Mixon T; Fitzsimmons P
    J Invasive Cardiol; 2006 Jun; 18(6):E166-8. PubMed ID: 16775892
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical experience with drug-eluting stents.
    Drachman DE
    Rev Cardiovasc Med; 2002; 3 Suppl 5():S31-7. PubMed ID: 12478233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry).
    Fröbert O; Lagerqvist B; Carlsson J; Lindbäck J; Stenestrand U; James SK
    J Am Coll Cardiol; 2009 May; 53(18):1660-7. PubMed ID: 19406341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome of percutaneous hybrid coronary revascularization: bare metal stents jeopardize the benefit of sirolimus-eluting stents in the real world.
    Fineschi M; Gori T; Pierli C; Casini S; Sinicropi G; Buti A; Del Pasqua A; Bravi A
    Can J Cardiol; 2005 Dec; 21(14):1281-5. PubMed ID: 16341297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Status of drug-eluting coronary stents.
    Chodosh A; Korr KS; Burtt D
    Med Health R I; 2008 Oct; 91(10):309-12, 314. PubMed ID: 19044106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Covered stents: a review.
    Jamshidi P; Mahmoody K; Erne P
    Int J Cardiol; 2008 Nov; 130(3):310-8. PubMed ID: 18672301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
    Grube E; Buellesfeld L
    Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-eluting stents: a mechanical and pharmacologic approach to coronary artery disease.
    Dobesh PP; Stacy ZA; Ansara AJ; Enders JM
    Pharmacotherapy; 2004 Nov; 24(11):1554-77. PubMed ID: 15537561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug-eluting stents for the treatment of in-stent restenosis: a clinical review.
    Yan BP; Ajani AE; Waksman R
    Cardiovasc Revasc Med; 2005; 6(1):38-43. PubMed ID: 16263355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.